This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.35% per year. These returns cover a period from January 1, 1988 through December 2, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Iovance (IOVA) Q1 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) first-quarter earnings lag estimates. The company is progressing well in terms of development of its lead pipeline candidate.
Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) Q1 revenues increase year over year. The company is progressing well with its pipeline. The company launches its third DMD drug, Vyondys 53, in quarter.
Arena (ARNA) Q1 Earnings Beat Estimates, Etrasimod Progresses
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) beats Q1 bottom-line estimates. The company progresses with the development of its key pipeline candidate, etrasimod.
Clovis (CLVS) Q1 Earnings Beat, COVID-19 Hurts Rubraca Sales
by Zacks Equity Research
Clovis (CLVS) reports lower-than-expected loss for first-quarter 2021. Lower new patient start amid COVID-19 hurts U.S. sales of Rubraca. Stock up.
Allogene (ALLO) Q1 Earnings & Sales Beat, Pipeline Advances
by Zacks Equity Research
Allogene (ALLO) beats earnings and revenue estimates in the first quarter. Stock gains 1.7%.
Ultragenyx (RARE) Q1 Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx Pharmaceutical (RARE) Q1 sales increase year over year while loss narrows
Repligen (RGEN) Beats on Q1 Earnings & Sales, Raises 2021 View
by Zacks Equity Research
Repligen (RGEN) reports encouraging first-quarter results with sales and earnings beating estimates. The company also raises its guidance for 2021. Stock up.
Atea Pharmaceuticals (AVIR) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Atea Pharmaceuticals (AVIR) has been struggling lately, but the selling pressure may be coming to an end soon
Atea Pharmaceuticals (AVIR) Is in Oversold Territory: What's Next?
by Zacks Equity Research
Atea Pharmaceuticals (AVIR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Geron (GERN) Begins Phase III Myelofibrosis Study on Imetelstat
by Zacks Equity Research
Geron (GERN) is evaluating its lead pipeline candidate, imetelstat, in late-stage studies for refractory myelofibrosis and myelodysplastic syndromes.
Tandem (TNDM) Grows on Abbott, Dexcom Pacts Amid COVID-19 Woes
by Zacks Equity Research
Tandem Diabetes (TNDM) is expects t:sport to be a major growth catalyst for 2022.
Illumina's (ILMN) Expanded NIPT Coverage Study Outcome Favorable
by Zacks Equity Research
Illumina's (ILMN) coverage for pregnant women under the age of 35 will provide access of NIPT to thousands of women with minimal financial impact.
Illumina (ILMN) NGS-Based Platform Approved for Use in Russia
by Zacks Equity Research
Illumina and R-Pharm's in-vitro diagnostics platform registration will drive the expansion of Next Generation Sequencing-based clinical diagnostics across Russia.
QIAGEN (QGEN) Unveils Digital Platform for Syndromic Testing
by Zacks Equity Research
QIAGEN's (QGEN) QIAsphere cloud-based platform will enhance QIAstat-Dx's potential by offering remote services round the clock to improve testing continuity.
Nasdaq Turns Red YTD: 5 Top-Ranked Stocks Up More Than 50%
by Sweta Killa
As the Nasdaq eroded all the gains made this year and turned red due to the tech sell-off, there are still some stocks that have gained more than 50% so far this year.
QIAGEN (QGEN) Launches QIAcube Connect MDx Platform Globally
by Zacks Equity Research
QIAGEN's (QGEN) QIAcube Connect MDx platform can be used with more than 140 standard protocols and it ensures complete consistency of the purification of multiple sample types.
Medtronic's (MDT) HVAD Pump Kit Recall Classified as Class I
by Zacks Equity Research
The latest back-to-back incidents will, undoubtedly, create a major drag in Medtronic's (MDT) VAD performance.
Allogene (ALLO) Q4 Earnings Top Estimates, Pipeline Advances
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the fourth quarter of 2020.
Bayer's (BAYRY) Q4 Earnings Match Estimates, Sales Miss
by Zacks Equity Research
Bayer (BAYRY) reports in-line earnings and misses sales estimates in the fourth quarter of 2020.
Horizon's (HZNP) Shares Rise on Q4 Earnings & Sales Beat
by Zacks Equity Research
Horizon (HZNP) beats earnings and sales estimates in the fourth quarter of 2020.
bluebird (BLUE) Q4 Loss Narrower than Expected, Sales Miss
by Zacks Equity Research
bluebird (BLUE) reports a narrower-than-expected loss but misses sales estimates in the fourth quarter of 2020.
Epizyme's (EPZM) Q4 Loss Wider than Expected, Sales Beat
by Zacks Equity Research
Epizyme (EPZM) incurs a wider-than-expected loss but beats sales estimates in the fourth quarter of 2020.
Cassava Sciences (SAVA) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cassava Sciences (SAVA) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.
Bionano (BNGO) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Bionano (BNGO) will provide updates on its revenues and earnings when it reports fourth-quarter and full-year 2020 results.
Seagen (SGEN), Astellas Submit 2 sBLAs to FDA for Urothelial Cancer
by Zacks Equity Research
Seagen (SGEN) and Astellas Pharma announced completion of submissions of two sBLAs to the FDA for Padcev in patients with locally advanced or metastatic urothelial carcinoma.